Last reviewed · How we verify
Coromec Registry with ECL-19 — Competitive Intelligence Brief
phase 2
ECL-19
Small molecule
Live · refreshed every 30 min
Target snapshot
Coromec Registry with ECL-19 (Coromec Registry with ECL-19) — Aventyn, Inc.. Coromec Registry with ECL-19 is a small molecule that targets the molecular target.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Coromec Registry with ECL-19 TARGET | Coromec Registry with ECL-19 | Aventyn, Inc. | phase 2 | ECL-19 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Coromec Registry with ECL-19 CI watch — RSS
- Coromec Registry with ECL-19 CI watch — Atom
- Coromec Registry with ECL-19 CI watch — JSON
- Coromec Registry with ECL-19 alone — RSS
Cite this brief
Drug Landscape (2026). Coromec Registry with ECL-19 — Competitive Intelligence Brief. https://druglandscape.com/ci/coromec-registry-with-ecl-19. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing